143 related articles for article (PubMed ID: 38273849)
1. Dual-phenotype hepatocellular carcinoma: correlation of MRI features with other primary hepatocellular carcinoma and differential diagnosis.
Zhang L; Chen J; Lai X; Zhang X; Xu J
Front Oncol; 2023; 13():1253873. PubMed ID: 38273849
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic Value of MRI Features in Dual-phenotype Hepatocellular Carcinoma: A Preliminary Study.
Gu HX; Huang XS; Xu JX; Zhu P; Xu JF; Fan SF
J Digit Imaging; 2023 Dec; 36(6):2554-2566. PubMed ID: 37578576
[TBL] [Abstract][Full Text] [Related]
3. Radiomics for diagnosis of dual-phenotype hepatocellular carcinoma using Gd-EOB-DTPA-enhanced MRI and patient prognosis.
Huang X; Long L; Wei J; Li Y; Xia Y; Zuo P; Chai X
J Cancer Res Clin Oncol; 2019 Dec; 145(12):2995-3003. PubMed ID: 31664520
[TBL] [Abstract][Full Text] [Related]
4. A multivariate model based on gadoxetic acid-enhanced MRI using Li-RADS v2018 and other imaging features for preoperative prediction of dual‑phenotype hepatocellular carcinoma.
Liu MT; Zhang JY; Xu L; Qu Q; Lu MT; Jiang JF; Zhao XC; Zhang XQ; Zhang T
Radiol Med; 2023 Nov; 128(11):1333-1346. PubMed ID: 37740839
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological Features and Post-resection Prognosis of Double Primary Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
Jung DH; Hwang S; Kim KH; Hong SM; Lee YJ; Ahn CS; Moon DB; Ha TY; Song GW; Park GC; Yu ES; Lee SG
World J Surg; 2017 Mar; 41(3):825-834. PubMed ID: 27812807
[TBL] [Abstract][Full Text] [Related]
6. Preoperative Diagnosis of Dual-Phenotype Hepatocellular Carcinoma Using Enhanced MRI Radiomics Models.
Wu Q; Yu YX; Zhang T; Zhu WJ; Fan YF; Wang XM; Hu CH
J Magn Reson Imaging; 2023 Apr; 57(4):1185-1196. PubMed ID: 36190656
[TBL] [Abstract][Full Text] [Related]
7. [The prediction value of enhanced magnetic resonance imaging nomogram model for dual phenotype hepatocellular carcinoma].
Wu Q; Yu YX; Fan YF; Hu S; Yao FR; Wang XM; Hu CH
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(15):1086-1092. PubMed ID: 35436807
[No Abstract] [Full Text] [Related]
8. Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using Gd-EOB-DTPA-enhanced magnetic resonance imaging combined with serum markers in at-risk patients with hepatitis B virus.
Han D; Li Y; He X; Zhang J; Zhou Y; Zhang J; Zhang L
Quant Imaging Med Surg; 2023 Oct; 13(10):7156-7169. PubMed ID: 37869332
[TBL] [Abstract][Full Text] [Related]
9. [Application value of neutrophil lymphocyte ratio combined with age in the diagnosis of dual-phenotype hepatocellular carcinoma].
Wang KD; Lu GY; Diao XP; Wang L; Zhou PC; Ma F; Fan XJ
Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(46):3686-3692. PubMed ID: 36509540
[No Abstract] [Full Text] [Related]
10. Overexpression of Epcam and CD133 Correlates with Poor Prognosis in Dual-phenotype Hepatocellular Carcinoma.
Zhang J; Qi YP; Ma N; Lu F; Gong WF; Chen B; Ma L; Zhong JH; Xiang BD; Li LQ
J Cancer; 2020; 11(11):3400-3406. PubMed ID: 32231746
[No Abstract] [Full Text] [Related]
11. Combined hepatocellular carcinoma-cholangiocarcinoma: MRI features correlated with tumor biomarkers and prognosis.
Zhou C; Wang Y; Ma L; Qian X; Yang C; Zeng M
Eur Radiol; 2022 Jan; 32(1):78-88. PubMed ID: 34279688
[TBL] [Abstract][Full Text] [Related]
12. Small intrahepatic mass-forming cholangiocarcinoma: target sign on diffusion-weighted imaging for differentiation from hepatocellular carcinoma.
Park HJ; Kim YK; Park MJ; Lee WJ
Abdom Imaging; 2013 Aug; 38(4):793-801. PubMed ID: 22829097
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular carcinoma expressing cholangiocyte phenotype is a novel subtype with highly aggressive behavior.
Lu XY; Xi T; Lau WY; Dong H; Zhu Z; Shen F; Wu MC; Cong WM
Ann Surg Oncol; 2011 Aug; 18(8):2210-7. PubMed ID: 21308485
[TBL] [Abstract][Full Text] [Related]
14. Microvascular invasion is associated with poor survival in patients with dual-phenotype hepatocellular carcinoma.
Ouyang X; Yan Y; Zhang S; Li M; Li M; Liu Q
Am J Clin Pathol; 2024 Mar; 161(3):245-255. PubMed ID: 37947176
[TBL] [Abstract][Full Text] [Related]
15. Analysis of clinicopathologic and imaging features of dual-phenotype hepatocellular carcinoma.
Huang K; He Y; Liang T; Mo S; Liao Y; Gao Q; Liao X; Han C; Zhu G; Peng T
Sci Rep; 2024 Feb; 14(1):3314. PubMed ID: 38332165
[TBL] [Abstract][Full Text] [Related]
16. Gadoxetic acid disodium-enhanced MR imaging of cholangiolocellular carcinoma of the liver: imaging characteristics and histopathological correlations.
Haradome H; Unno T; Morisaka H; Toda Y; Kwee TC; Kondo H; Sano K; Ichikawa T; Kondo F; Sugitani M; Takayama T
Eur Radiol; 2017 Nov; 27(11):4461-4471. PubMed ID: 28439650
[TBL] [Abstract][Full Text] [Related]
17. Scirrhous hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging and diffusion-weighted imaging: emphasis on the differentiation of intrahepatic cholangiocarcinoma.
Park MJ; Kim YK; Park HJ; Hwang J; Lee WJ
J Comput Assist Tomogr; 2013; 37(6):872-81. PubMed ID: 24270108
[TBL] [Abstract][Full Text] [Related]
18. Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?
Huang JY; Li JW; Ling WW; Li T; Luo Y; Liu JB; Lu Q
World J Gastroenterol; 2020 Jul; 26(27):3938-3951. PubMed ID: 32774068
[TBL] [Abstract][Full Text] [Related]
19. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.
Tang Y; Wang L; Teng F; Zhang T; Zhao Y; Chen Z
Int J Med Sci; 2021; 18(1):187-198. PubMed ID: 33390787
[No Abstract] [Full Text] [Related]
20. The significance of the predominant component in combined hepatocellular-cholangiocarcinoma: MRI manifestation and prognostic value.
Sheng R; Yang C; Zhang Y; Wang H; Zheng B; Han J; Sun W; Zeng M
Radiol Med; 2023 Sep; 128(9):1047-1060. PubMed ID: 37474663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
